|
|
News Breaks | | | | September 28, 2012 | | 07:28 EDT |  | ACHN | Achillion price target raised to $15 from $10 at JMP Securities
JMP Securities raised its target on Achillion as the firm is impressed by the initial proof of concept data for ACH-3102. The firm thinks Achillion could become a major competitor in the HCV genotype-1 sector, and it reiterates an Outperform rating on the stock. | |
|
News For ACHN From The Last 14 Days Check below for free stories on ACHN the last two weeks. |
|
|
| May 16, 2013 | | 10:30 EDT |  | ACHN | Achillion management to meet with Maxim
 Subscribe for More Information | | | May 15, 2013 | | 06:06 EDT |  | ACHN | Achillion appoints Dr. David Apelian as Chief Medical Officer
Achillion (ACHN) appointed David Apelian, M.D., Ph.D., MBA, to the position of Executive VP and Chief Medical Officer, effective May 28. Dr. Apelian wll assume responsibility for the clinical development of Achillion's portfolio of compounds to treat HCV. In addition, Achillion also expanded its clinical operations group with the recent addition of Kevin Kucharski, formerly head of clinical operations at Pharmasset (VRUS), who will serve as Senior VP of Clinical Operations. | |
|
|
|
|
|
|
